financetom
Business
financetom
/
Business
/
IonQ Names Inder Singh CFO, COO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IonQ Names Inder Singh CFO, COO
Sep 4, 2025 5:17 AM

07:54 AM EDT, 09/04/2025 (MT Newswires) -- IonQ ( IONQ ) said Thursday it has appointed Inder M. Singh as chief financial officer and chief operating officer.

Singh, who will succeed Thomas Kramer, most recently served as CFO of Arm, IonQ ( IONQ ) said.

Kramer will remain with the company in an advisory capacity for up to 60 days, the company added.

Additionally, Singh will step down from IonQ's ( IONQ ) board of directors, the company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
Nov 15, 2024
07:03 AM EST, 11/14/2024 (MT Newswires) -- AtkinsRealis ( SNCAF ) on Thursday said third-quarter adjusted profit and revenue rose. The engineering services and nuclear company said adjusted profit attributable to shareholders from professional services and project management (PS&PM) increased 64% to $110.1 million, or $0.63 per diluted share, from $67.3 million, or $0.38 per diluted share, last year. Services...
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Nov 15, 2024
(Reuters) - U.S. farmers struggling with slumping incomes and depressed grain prices have been switching to cheaper generic pesticides and fungicides as they plan for spring planting next year, which market analysts said could hit the bottom lines of agrichemical companies like Bayer. Signs of these financial impacts are already emerging. Bayer shares fell sharply to a 20-year low on...
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
Nov 15, 2024
07:05 AM EST, 11/14/2024 (MT Newswires) -- GSK (GSK) said Thursday that the interim analysis of the DREAMM-7 head-to-head phase three trial evaluating Blenrep, or belantamab mafodotin, in combination with bortezomib plus dexamethasone, or BorDex, as a second-line or later treatment for relapsed or refractory multiple myeloma showed positive headline results. The trial met its key secondary endpoint of overall...
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Nov 15, 2024
Nov 14 (Reuters) - Merck ( MRK ) has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck ( MRK ) to take over development of LaNova's LM-299, a drug candidate targeting a protein called PD-1, which...
Copyright 2023-2026 - www.financetom.com All Rights Reserved